During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

March Biosciences (March Bio), a clinical stage biotechnology company developing cell therapies for hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted ...

The discovery of new cancer cells with a switched-on gene called ZBTB16 is a breakthrough in childhood blood cancer research.

Artiva remains on track to share initial clinical response data and conduct U.S. Food and Drug Administration (FDA) regulatory interactions to align on pivotal trial design for AlloNK in refractory ...

Tesla's new Tera-Cell battery promises 600+ mile range and 15-minute charging! Discover how this game-changing tech will end range anxiety, revolutionize travel, and make Tesla's flying car dream a ...

If it reaches production, the car is expected to sit on Ola’s Gen 4 platform, an adaptable architecture designed to support ...

Under the floodlights near Munich Airport, Audi turned a hangar into a Formula 1 launchpad. The R26 Concept rolled out of the ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of ...

The treatment landscape for systemic lupus erythematosus (SLE) has shifted greatly in recent years, driven by the emergence of cell-based immunotherapies targeting pathogenic B-cell populations. Among ...

New research suggests that DNA variants help predict toxicity and response in CAR T-cell therapy for large B-cell lymphoma.

In a licensing deal unveiled Monday, Lyell Immunopharma is handing over $40 million in cash and almost 2 million of its ...